Hot Life Science Investor Mandate 3: Global Firm With Patient-Centric Strategy Invests In Oncology, Cardiovascular, Anti-infectives, CNS/pain, and Women’s Health

26 Nov

A global healthcare investment firm, headquartered in New York, is investing from an evergreen Life Sciences investment fund.

Typical allocations are up to $5M in early stage projects and $10-15M in late stage projects. With follow-on allocations, the total investment can reach up to $30M per company. The firm takes a mid- to long-term investment approach. The firm leverages flexible capital structures and can invest in both private and public companies. The firm often syndicates with major US venture capital firms, but it can also lead a financing round. The firm is currently seeking new opportunities with 80% focus on US and Canada and 20% on Western Europe.

The firm puts 70% focus on therapeutics and 30% on medical devices. In therapeutics, the firm prefers late-stage assets with human proof of concept and blockbuster potential, while it also has a minor interest in early-stage breakthrough science with strong management teams. In medical devices, the firm seeks to provide growth funding in de-risked medical devices and diagnostics in final approval steps, launch and international marketing efforts. The firm considers both single assets and platform technologies. The firm’s investment strategy is strictly patient-centric.

The firm focuses on five key disease areas: oncology, cardiovascular, anti-infectives, CNS/pain, and women’s health. In oncology, the firm seeks therapies with novel mechanisms of action and delivery, human data and signs of efficacy, and it also considers new generation diagnostics technologies. In cardiovascular diseases, the firm seeks life-saving therapies and technologies with strong human data. In anti-infectives the firm is considering pre-clinical assets managed by serial entrepreneurs. In CNS, the firm seeks therapies with human proof-of-concept and clear mechanism of action. In women’s health, the firm seeks a wide range of therapies and technologies at all stages, which help women give birth to healthy children.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: